Coya Therapeutics (COYA) reported the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical inflammatory associated mouse model of Parkinson's Disease. In an inflammatory mouse model of Parkinson's Disease, subcutaneous injections of COYA 302 significantly reduced inflammation and microglial activation in nigrostriatal brain regions responsible for motor control. Also, subcutaneous injections of COYA 302 resulted in reductions in astrocyte numbers and their activation in the nigrostriatal pathway.
The company expects presenting and/or publishing these data in a peer reviewing setting.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.